

GENERIC PHARMASEC LIMITED

(Formerly known as Adi Rasayan Limited)

Registered Office: 7th Floor Purva Plaza, Shimpoli Signal, Near Reliance Energy,
off S.V. Road, Borivali (West), Mumbai- 400 092.

Website: www.genpharmasec.com Telephone: 8655550242

Email Id: compliance@genpharmasec.com/ info@genpharmasec.com

CIN: L24231MH1992PLC323914

Date: 13/08/2019

To,
Department of Corporate Services,
BSE LIMITED
P. J. Towers, Dalal Street,
Mumbai - 400 001.

Dear Sir/ Madam,

Subject:- Outcome of Board Meeting held on Tuesday, 13th August, 2019

Ref: BSE Scrip Code: 531592

In terms of the provisions of Regulation 30 (read with Part A of schedule III) and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following statements for the quarter ended June 30, 2019, which were approved & taken on record by our Board of Directors at its meeting held today, the August 13, 2019.

- Un-Audited Standalone Financial Results along with Limited Review Report for 1st quarter ended on June 30, 2019.
- Considered and approved the Board Report for the year ended 31/03/2019.
- Considered and appointed Mr. Jaymin Modi, Practicing Company Secretary to act as Scrutinizer for E-voting & poll at the ensuing Annual General Meeting.
- Fixed the Date, Time & Venue of 27th Annual General Meeting of the Company as 25th September, 2019 at 09.30 A.M. and approved the Notice for the same.
- Considered and approved, Post completion of Open Offer as per SEBI (SAST) Regulations, 2011 read with Regulation 31A SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015, the induction of the following Person /Entity from "Public Category" to "Promoter & Promoter Group Category" as under:

i. From "Public Category" to "Promoter & Promoter Group Category":

- Sneha Sadhwani
- Rajesh Sadhwani

The Induction is subject to the approval of the Members of the Company and Regulatory Authority.

Kindly take the same on your records.

Thanking You,

Yours Truly,

For Generic Pharmasec Limited
(Formerly Known as Adi Rasayan Limited)


Dollar Chheda
Director
DIN: 08490484

ENCL: A/A



GENERIC PHARMASEC LIMITED

(Formerly known as ADI RASAYAN LTD)

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019

(Amount in Lakhs)

Particulars	Quarter Ended (June 30, 2019)	Preceding Quarter Ended (March 31, 2019)	Corresponding Quarter Ended (June 30, 2018) of Previous Year	Year Ended 31st March, 2019
	Unaudited	Audited	Unaudited	Audited
1 Revenue from Operations	64.98	-	-	37.51
2 Other Income	13.84	19.99	-	37.50
3 Total Revenue (1 + 2)	78.82	19.99	-	75.01
4 Expenses				
Cost of materials consumed	-	-	-	-
Purchase of stock-in-trade	79.31	525.00	-	525.00
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(19.79)	(525.00)	-	(525.00)
Employee benefits expense	1.64	0.43	0.44	1.70
Depreciation and amortisation expense	0.08	0.01	0.01	0.02
Other Expenses	13.26	9.95	1.82	44.53
Total expenses	74.49	10.38	2.27	46.26
5 Profit/(Loss) Before Exceptional and Extraordinary items and Tax (3-4)	4.33	9.62	(2.27)	28.75
6 Exceptional items	-	-	-	-
7 Profit/(Loss) Before Tax (5-6)	4.33	9.62	(2.27)	28.75
8 Tax expenses				
(1) Current Tax	-	5.65	-	5.65
(2) Deferred Tax	-	(0.01)	-	(0.01)
9 Profit / (Loss) from continuing operations (7 - 8)	4.33	3.97	(2.27)	23.11
10 Profit / (Loss) from discontinuing operations	-	-	-	-
11 Tax expense of discontinuing operations	-	-	-	-
12 Profit/(loss) from Discontinuing operations (after tax)	-	-	-	-
13 Profit (Loss) for the period (9+12)	4.33	3.97	(2.27)	23.11
14 Other Comprehensive income;				
A (i) Items that will not be reclassified to profit or loss	(132.78)	(63.68)	-	(61.58)
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
B (i) Items that will be reclassified to profit or loss	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
15 Total Comprehensive Income for the period (9+10) (Comprising profit/ (loss) and other Comprehensive Income for the period	(128.45)	(59.70)	(2.27)	(38.47)
16 Earnings per equity share (before extraordinary items) of face value of Re. 1 each				
(a) Basic	0.00	0.00	(0.70)	0.03
(b) Diluted	0.00	0.00	(0.70)	0.03




Notes:

- 1 The above result were reviewed by the Audit Committee and approved by the Board Of directors at their meeting on 13th August, 2019.
- 2 The above result have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act 2013, and other recognized accounting practices and policies to the extent applicable.
- 3 Figures for the corresponding quarter ended in the previous year as reported in these financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of the third quarter of the relevant financial year.
- 4 Previous period figures have been regrouped/reclassified as considered necessary to facilitate comparison.
- 5 During the period under review the Board Directors of the Company at their meeting have approved the issue and allotment of 10,00,000 Equity shares in Conversion of 10,00,000 warrants of Rs. 10/- each fully paid on preferential allotment basis. Thus the EPS figure of quarter ended 31.3.2019 and year to date 31.03.2019 is non-comparable with other EPS figures.
- 6 The Face value per share of the company has been subdivided from FV Rs. 10/- per share to FV Rs. 1/- per share vide Board Meeting date 28.02.2019 approved by the shareholders in extra ordinary meeting dated 30.3.2019, approved from stock exchange dated 11.04.2019 (effective date).

For and on behalf of the Board of
GENERIC PHARMASEC LIMITED
(Formerly known as ADI RASAYAN LTD)




(Dollar Azad Chheda)
Director
DIN : 08490484

PLACE : MUMBAI
DATE : 13.08.2019



To
Board of Directors of

Generic Pharmasec Limited
(Formerly Known as "Adi Rasayan Limited")
7th Floor, Purva Plaza,
Off S.V. Road, Borivali (west),
Mumbai- 400092 Maharashtra

We have reviewed the accompanying statement of unaudited financial results of Generic Pharmasec Limited (Formerly Known as "Adi Rasayan Limited") for the quarter ended 30th June, 2019 and the year to date results for the period from 1 April, 2019 to 30th June, 2019 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of Companies (Indian Accounting Standards) Rule, 2015, as amended, read with the Circular, is the responsibility of the Company's Management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian accounting Standards ('Ind AS') prescribed under s.133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KOSHAL & ASSOCIATES
Chartered Accountants
Firm Reg.No.121233W


Koshal Maheshwari
Proprietor
M.No.043746

Place of signature: Mumbai
Date: 13.08.2019

UDIN:19043746AAAAAY5132